← SynDRA
POSACONAZOLE
SynDRA canonical compound SYN0006043 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP3A4 | CYP51A1 |
|---|
| Mechanism of action | sterol demethylase inhibitor |
|---|
| Indication | oropharyngeal candidiasis |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CYP3A4
- ABCG2
- CYP51
- CYP51A1
- CYP8B1
- Candi ERG11
- ERG11
- cyp51A
- cyp51B
Mechanisms of action (all sources)
- sterol demethylase inhibitor
- Inhibitor
- ERG11 INHIBITOR
Drug classes
- Azole Antifungal
- 14-alpha Demethylase Inhibitors
- Anti-Infective Agents
- Antifungal Agents
- Antiparasitic Agents
- Antiprotozoal Agents
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Hormone Antagonists
- Metabolic Side Effects of Drugs and Substances
- Steroid Synthesis Inhibitors
- Trypanocidal Agents
ATC classes
- J02A · ANTIMYCOTICS FOR SYSTEMIC USE
Cross-references
Synonyms
- noxafil
- posaconazol
- SCH-56592
- Posaconazol
- (-)-posaconazole
- Noxafil
- Noxafil powdermix kit
- Posaconazole accord
- Posaconazole ahcl
- Posaconazole sp
- Spriafil
- Posaconazole SP
- Posaconazole in combination with MGCD290
- SCH56592
- X2N
- Noxafil (TN)
- Noxafil, Posaconazole
- Posaconazole (USAN/INN)
- Posaconazole [USAN:INN:BAN]
- 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
- 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
- 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
- 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
- Schering 56592
- 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE
- (-)-POSACONAZOLE
- 6TK1G07BHZ
- CHEMBL1397
- CHEBI:64355
- 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol
- D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)- 4-((4-(4-(4-(1-((1S,2S)-1-ety
- POS
- UNII-6TK1G07BHZ
- pasaconazole
- HSDB 7421
- 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-
- 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3R-[3alpha(1S*,2S*),5alpha]]-
- 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one
Reported adverse events
- Cough
- Hypersensitivity
- Hypertension
- Nausea
- Rash
- Thrombocytopenia
- Vomiting
- Arrhythmia
- Asthenia
- Constipation
- Epistaxis
- Headache
Look up POSACONAZOLE in the interactive SynDRA portal →